Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologic or cytologic diagnosis of NSCLC Stage IIIB or IV~* no prior systemic chemotherapy for advanced Non-Small Cell Lung Cancer~* Prior radiotherapy must be completed at least 4 weeks before study enrollment.~Exclusion Criteria:~* estimated life expectancy of 12 weeks~* a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease~* documented brain metastases unless the patient has completed successful local therapy for central nervous system metastases and has been off of corticosteroids for at least 2 weeks before enrollment~* significant weight loss (that is, \> 10%) over the previous 6 weeks before study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).